Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death - Implications for vascular disease and therapy

被引:105
作者
Sata, M
Suhara, T
Walsh, K
机构
[1] Tufts Univ, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA
[2] Tufts Univ, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA
[3] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan
关键词
Fas; adenovirus; smooth muscle cells; endothelial cells; apoptosis;
D O I
10.1161/01.ATV.20.2.309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fas ligand (FasL) is a death factor that induces apoptosis in cells bearing its receptor, Fas. Fas and Fast have been detected in the vessel wall, and it has been proposed that Fas-mediated apoptosis has a role in physiological and pathological cell turnover in the vasculature. Here, we evaluated the expression of Fas in the presence and absence of cytokines on both endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). We also examined the sensitivity of ECs and VSMCs to Fas-mediated apoptosis induced by exposure to multiple Fas agonists: soluble Fast, anti-Fas antibody, and membrane-bound Fast resulting from transduction with a replication-defective adenovirus expressing Fast (Adeno-FasL), Cell-surface Fast expression was detected on human ECs with the use of 4 anti-Fast antibodies, whereas cell-surface Fast expression was not detected on VSMCs. Unstimulated ECs expressed relatively low levels of Fas, but expression was upregulated after treatment with tumor necrosis factor-alpha (TNF-alpha) or interferon gamma (IFN-gamma). In contrast, VSMCs expressed relatively high levels of Fas, and treatment with TNF-alpha or IFN-gamma induced little or no upregulation under the conditions of these assays. ECs were resistant to death after exposure to soluble Fast or agonist anti-Fas antibody and also after infection with Adeno-FasL in the presence or absence of cytokine treatment. In contrast, VSMCs remained viable in the presence of soluble Fast or agonist anti-Fas antibody, but they underwent apoptosis after infection with Adeno-FasL, IFN-gamma enhanced Adeno-FasL-induced death of VSMCs, but TNF-alpha did not. These findings provide insights about the potential role of Fas-mediated apoptosis in the vessel wall and suggest strategies to treat proliferative vascular diseases by exploiting the differential sensitivity of ECs and VSMCs to Fast-induced cell death.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 45 条
  • [1] An essential role for NF-kappa B in preventing TNF-alpha-induced cell death
    Beg, AA
    Baltimore, D
    [J]. SCIENCE, 1996, 274 (5288) : 782 - 784
  • [2] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [3] Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
    Bennett, M
    Macdonald, K
    Chan, SW
    Luzio, JP
    Simari, R
    Weissberg, P
    [J]. SCIENCE, 1998, 282 (5387) : 290 - 293
  • [4] Development of inflammatory angiogenesis by local stimulation of Fas in vivo
    Biancone, L
    DeMartino, A
    Orlandi, V
    Conaldi, PG
    Toniolo, A
    Camussi, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) : 147 - 152
  • [5] BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19
  • [6] Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells
    Bossi, G
    Griffiths, GM
    [J]. NATURE MEDICINE, 1999, 5 (01) : 90 - 96
  • [7] The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions
    Cai, WJ
    Devaux, B
    Schaper, W
    Schaper, J
    [J]. ATHEROSCLEROSIS, 1997, 131 (02) : 177 - 186
  • [8] The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection
    Dockrell, DH
    Badley, AD
    Villacian, JS
    Heppelmann, CJ
    Algeciras, A
    Ziesmer, S
    Yagita, H
    Lynch, DH
    Roche, PC
    Leibson, PJ
    Paya, CV
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) : 2394 - 2405
  • [9] Dong CM, 1996, LAB INVEST, V74, P921
  • [10] FIEDLER P, 1998, SCIENCE, V279, pA2015